Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire - Wed May 27, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress PR Newswire - Thu May 21, 4:17PM CDT

SOUTH SAN FRANCISCO, Calif. , May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference PR Newswire - Thu May 14, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer PR Newswire - Tue May 12, 6:00AM CDT

SOUTH SAN FRANCISCO, Calif. , May 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel: Q1 Earnings Snapshot AP - Tue May 5, 3:36PM CDT

Rigel: Q1 Earnings Snapshot

RIGL : 30.30 (+0.93%)
Rigel Reports First Quarter 2026 Financial Results PR Newswire - Tue May 5, 3:01PM CDT

SOUTH SAN FRANCISCO, Calif. , May 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel's MDS Candidate Timeline Collides With Product Sales Momentum Question Barchart - Mon May 4, 4:26PM CDT

Barchart Research What to Expect from RIGL Earnings RIGL Generated May 4, 2026 Current Price $29.54 EPS Estimate $$0.74 Consensus Rating Moderate Buy Average Move 17.65% Rigel's MDS Candidate Timeline...

RIGL : 30.30 (+0.93%)
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results PR Newswire - Tue Apr 28, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market...

RIGL : 30.30 (+0.93%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Tue Apr 7, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals,...

RIGL : 30.30 (+0.93%)
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology PR Newswire - Tue Mar 31, 7:05AM CDT

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC

RIGL : 30.30 (+0.93%)

Barchart Exclusives

Circle Stock Slips as Stripe, Visa, Mastercard Explore Stablecoin Platform Barchart - Wed Jun 3, 3:43PM CDT
Circle stock sinks on reports of Stripe, Visa, and Mastercard nearing launch of a joint stablecoin platform. But should you buy the dip in CRCL shares today? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.